Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.64
−$0.06 · -1.62%
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Regular session
$3.64
−$0.06 · -1.62%
Regular session · ET · Market data may be delayed.
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Day range
Current $3.64
52-week range
Current $3.64
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
58
Fair Value
Sentiment
61
Bullish
Risk
63
High Risk
Momentum
58
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Day range
Current $3.64
52-week range
Current $3.64
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.5M USD | 652K USD | 350K USD | 294.95M USD | 295.84M USD |
| Cost of goods sold | 1.64M USD | — | — | 185.94M USD | 173.95M USD |
| Gross profit | 1.86M USD | 652K USD | 350K USD | 109.01M USD | 121.89M USD |
| Research and development | 38.2M USD | 38.82M USD | 40.62M USD | 24.57M USD | 28.44M USD |
| Selling, general, and administrative | 17.36M USD | 14.92M USD | 11.61M USD | 99.21M USD | 100.9M USD |
| Operating expenses | 53.92M USD | 53.74M USD | 52.23M USD | 133.7M USD | 134.76M USD |
| Interest income | 2.17M USD | 1.33M USD | 2.81M USD | 989K USD | — |
| Interest expense | — | — | — | 6.26M USD | 5.19M USD |
| Depreciation and amortization | 1.64M USD | 1.7M USD | 1.68M USD | 878K USD | 22.8M USD |
| Operating income | −52.06M USD | −53.09M USD | −51.88M USD | −24.69M USD | −13.47M USD |
| Net income | −80.4M USD | −51.79M USD | −49.29M USD | −32.49M USD | −27.99M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$10.50
188.46% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 25, 1996 | 2:1 | — | — |
Effective Mar 25, 1996
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.9M0.00%2.3T USD0.03%$381.36+0.47%
iShares Russell 2000 ETFIWM2.7M0.00%77.7B USD0.19%$278.37+0.29%
Vanguard Extended Market ETFVXF1.49M0.00%95.4B USD0.05%$234.27+0.49%
iShares Russell 2000 Growth ETFIWO1.1M0.01%14.04B USD0.24%$355.56+0.59%
Vanguard Russell 2000 ETFVTWO715.78K0.00%18B USD0.06%$112.43+0.29%
iShares Micro-Cap ETFIWC366.5K0.03%1.32B USD0.60%$182.68-0.06%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC202.06K0.02%1.04B USD0.20%$86.145+0.26%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM200K0.17%116.54M USD0.73%$15.96+0.38%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
